SAN FRANCISCO and GENEVA, Aug. 2, 2021 /PRNewswire/ -- FIND, the global alliance for diagnostics, and Kountable, a global trade and technology platform, have teamed up on a new initiative to address challenges faced by procurement bodies related to governance, risk, liquidity and the high costs of working capital that negatively impact diagnostic supply chains in low- and middle-income countries (LMICs).
Diagnostic developers generally negotiate and publish "ex-works" prices, being the price to the first vendor in the supply chain when the tests leave the factory. However, the tests change hands multiple times as they are imported and exported through different channels, and finally distributed within the destination country. There is often a delay between local distributors paying to receive a shipment and then subsequently being reimbursed by the local authority or hospital that is buying them, leaving the distributor out of pocket. This gap between financial outlay and receipt of payment means the distributor often must borrow working capital, which can be a time-consuming, paper-driven process, and expensive due to high interest rates charged by local banks.
With mark ups being added at each stage of the journey, the final price to the end user can be significantly higher than the procurement prices negotiated with manufacturers. The trade finance and governance initiative announced today aims to address these challenges by tracking tests all along the supply chain, to ensure transparency and governance of the process, as well as the pooling of demand to reduce the out-of-pocket costs borne by local entities.
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
Ben Ndungu, CEO of Biodesk, a wholesaler in Kenya, said: "Transactions are registered through Kountable's simple-to-use application. Kountable is extremely convenient and ensured seamless execution of the project. The success of this project gave us the confidence to pursue larger deals and we are immensely lucky to have discovered Kountable when we did."
For the 12-month impact assessment, validated buyers and distributors in Kenya and Rwanda will be connected via Kountable's online platform, enabling them to purchase quality-assured diagnostics for COVID-19 and diabetes. For COVID-19, products will be limited to those antigen rapid tests (Ag RDTs) that have received World Health Organization Emergency Use Listing (EUL); i.e. those manufactured by Abbott, SD Biosensor and Premier Medical Corporation. For diabetes, a range of blood-glucose monitoring products that are approved by a stringent regulatory authority and locally registered in Kenya and Rwanda will be available.